Metformin combined with CB-839 specifically inhibits KRAS-mutant ovarian cancer
Sign Up to like & getrecommendations! Published in 2025 at "Scientific Reports"
DOI: 10.1038/s41598-025-90963-8
Abstract: KRAS mutations can cause metabolic reprogramming in ovarian cancer, leading to an increased metastatic capacity. This study investigated the metabolic reprogramming changes induced by KRAS mutations in ovarian cancer and the mechanism of action of… read more here.
Keywords: mutant ovarian; metformin combined; combined 839; kras mutant ... See more keywords